Bright Minds Biosciences Inc (DRUG)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $227.96M
Last updated: Nov 17, 2026 at 11:03 AM ET
Bright Minds Biosciences Inc (DRUG) Financials: Revenue, Profit and Cash Flow
Bright Minds Biosciences reported revenue of CAD 0 for the fiscal year ended Sep 30, 2025. That year, net income was CAD -12.23M, operating cash flow was CAD -8.69M and free cash flow was CAD -8.69M. The quarter ended Jun 30, 2026 had revenue of CAD 0 and net income of CAD -2.46M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Sep 2025, with an operating loss of CAD 13.94M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Sep 2025 | 0 | N/A | N/A | N/A | N/A |
| Sep 2024 | 0 | N/A | N/A | N/A | N/A |
| Sep 2023 | 0 | N/A | N/A | N/A | N/A |
| Sep 2022 | 0 | N/A | N/A | N/A | N/A |
| Sep 2021 | 0 | N/A | N/A | N/A | N/A |
| Sep 2020 | 0 | N/A | N/A | N/A | N/A |
| Sep 2019 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Sep 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 |
|---|---|---|---|---|---|---|---|
| Cost of revenue | 55.19K | N/A | 72.45K | 6.04K | N/A | N/A | N/A |
| Gross profit | -76.98K | N/A | -72.45K | -6.04K | N/A | N/A | N/A |
| Research and development | 11.08M | 1.18M | 5.00M | 12.18M | 6.31M | 354.85K | 126.03K |
| Operating income | -13.94M | -2.82M | -7.39M | -14.98M | -8.76M | -469.36K | -236.15K |
| Net income | -12.23M | -2.80M | -7.37M | -14.96M | -8.52M | -485.94K | -236.15K |
| EBITDA | -12.15M | -2.73M | -7.30M | -14.96M | -8.76M | -469.36K | -78.72K |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit | -19.97K | -20.13K | -19.77K | -12.21K | -11.64K | N/A | N/A | N/A | -18.11K | -18.11K | -18.11K | -18.11K |
| Operating income | -11.73M | -15.57M | -6.90M | -5.66M | -3.30M | -3.35M | -1.62M | -791.31K | 234.74K | -558.06K | -1.70M | -1.55M |
| Net income | -2.46M | -10.63M | -7.57M | -4.09M | -5.24M | -2.95M | 49.61K | -773.44K | 229.90K | -574.14K | -1.68M | -1.53M |
Balance Sheet
As of Sep 2025, cash and equivalents exceeded short-term debt of CAD 84.53K by 82.82M.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | 84.42M | 6.10M | 6.88M | 12.09M | 20.04M | 880.22K | 163.97K |
| Current assets | 84.31M | 5.99M | 6.81M | 11.95M | 20.04M | 878.22K | 79.99K |
| Cash and equivalents | 82.91M | 5.72M | 6.75M | 11.63M | 19.76M | 799.93K | 79.99K |
| Total liabilities | 2.38M | 568.26K | 280.86K | 1.54M | 638.57K | 150.92K | 36.71K |
| Short-term debt | 84.53K | 79.38K | 73.55K | 67.93K | N/A | N/A | N/A |
| Shareholder equity | 82.04M | 5.54M | 6.60M | 10.54M | 19.40M | 729.29K | 127.26K |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 310.84M | 312.15M | 90.88M | 84.42M | 52.50M | 56.47M | 58.40M | 6.10M | 6.28M | 6.53M | 6.89M | 6.88M |
| Total liabilities | 2.55M | 3.83M | 1.60M | 2.38M | 667.83K | 726.81K | 571.59K | 568.26K | 178.63K | 845.79K | 854.16K | 280.86K |
| Cash and equivalents | 308.16M | 309.30M | 89.05M | 82.91M | 51.39M | 55.68M | 57.90M | 5.72M | 6.19M | 5.93M | 6.76M | 6.75M |
| Shareholder equity | 308.30M | 308.32M | 89.28M | 82.04M | 51.83M | 55.74M | 57.83M | 5.54M | 6.10M | 5.69M | 6.03M | 6.60M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Sep 2025.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -8.69M | -1.85M | -7.02M | -13.59M | -7.32M | -288.39K | -42.01K |
| Capital expenditures | 0 | 0 | 5 | 0 | 0 | 0 | 0 |
| Free cash flow | -8.69M | -1.85M | -7.02M | -13.59M | -7.32M | -288.39K | -42.01K |
| Financing cash flow | 85.57M | 810.57K | 2.19M | 5.20M | 26.06M | 1.01M | 122.00K |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -8.42M | N/A | -5.82M | -1.27M | -3.50M | -2.43M | -1.49M | -463.17K | 240.16K | -805.09K | -822.09K | -1.20M |
| Free cash flow | -8.42M | N/A | -5.82M | -1.27M | N/A | -2.43M | -1.49M | -463.17K | 240.16K | -805.09K | -822.09K | -1.20M |
Frequently Asked Questions About DRUG
What is Bright Minds Biosciences' annual revenue?
Bright Minds Biosciences reported revenue of CAD 0 for the fiscal year ended Sep 30, 2025.
Is Bright Minds Biosciences profitable?
No. Bright Minds Biosciences reported net income of CAD -12.23M for the fiscal year ended Sep 30, 2025.
How much free cash flow does DRUG generate?
For the fiscal year ended Sep 30, 2025, operating cash flow of CAD -8.69M minus capital expenditures of CAD 0 produced free cash flow of CAD -8.69M.
How much debt does Bright Minds Biosciences have?
The balance sheet dated Sep 30, 2025 reported short-term debt of CAD 84.53K and cash and equivalents of CAD 82.91M.
DRUG pages: Overview, Financials, Competitors